[
  {
    "question": "Congenital myopathy scenario (details of dysmorphic feature of neonate) biopsy provided showed central core, what is the gene?",
    "option_a": "RYR1",
    "option_b": "neublin",
    "option_c": "?",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Central core disease is a congenital myopathy characterized by well\u2010defined, central areas (cores) in muscle fibers that lack oxidative enzyme activity. It is part of the congenital myopathies spectrum and often presents with hypotonia and weakness from birth. The key gene implicated is RYR1, which encodes the ryanodine receptor, a critical calcium channel in skeletal muscle. Mutations in the RYR1 gene disrupt normal calcium release from the sarcoplasmic reticulum, impairing muscle contraction. The central cores seen on muscle biopsy represent zones with mitochondrial depletion and disorganized myofibrils. This genetic defect may also predispose patients to malignant hyperthermia. Patients commonly present in infancy with hypotonia, proximal muscle weakness, and sometimes skeletal deformities. The presence of dysmorphic features in neonates can be part of the overall presentation. The histopathological finding of central cores is a diagnostic clue, linking the clinical presentation with an RYR1 mutation. Differential diagnoses include other congenital myopathies such as nemaline rod myopathy (associated with nebulin mutations) and centronuclear myopathy. Muscle biopsy, enzyme histochemistry, and genetic testing are key in differentiating these conditions. In central core disease, the central zones with absent oxidative enzymes are distinctive. Management is largely supportive and includes physiotherapy, orthopedic interventions for skeletal deformities, and monitoring for malignant hyperthermia risk during anesthesia. Genetic counseling is recommended. In the context of pregnancy and lactation, multidisciplinary management is important; anesthetic risk (malignant hyperthermia susceptibility) should be communicated with obstetric and anesthesia teams to avoid triggering agents. Option A is correct because central core disease is caused by mutations in the RYR1 gene. Option B (nebulin) is associated with nemaline myopathy, not central core disease. Options C and D are not provided, making A the sole appropriate choice. 1. RYR1 mutations not only cause central core disease but also predispose to malignant hyperthermia. 2. Muscle biopsy showing central cores is a classic histological finding. 3. Early diagnosis helps in planning safe anesthesia, especially in infants. Recent advances in genetic sequencing have improved the detection of RYR1 mutations, aiding early diagnosis. Updated guidelines emphasize the importance of genetic counseling and risk stratification for malignant hyperthermia in affected patients.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Dysferlinopathy scenario (mentioned GASTROCNEMIUS MUSCLE ATROPHY):",
    "option_a": "Dysferlinopathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dysferlinopathies are a group of muscular dystrophies caused by mutations in the dysferlin gene. They encompass conditions such as Limb-Girdle Muscular Dystrophy type 2B and Miyoshi Myopathy. The scenario describing gastrocnemius muscle atrophy is classic for these conditions. Dysferlin is a protein involved in repairing the sarcolemma (muscle cell membrane) after injury. Mutations in the dysferlin gene lead to defective membrane repair and subsequent muscle fiber degeneration. Over time, repeated muscle injury and inadequate repair result in muscle weakness and atrophy, particularly in the lower limbs. Patients often present in young adulthood with progressive muscle weakness and atrophy, typically starting in the distal muscles of the legs (such as the gastrocnemius) in Miyoshi myopathy, or more proximally in LGMD2B. Elevated creatine kinase levels and muscle biopsy showing absent or markedly reduced dysferlin confirm the diagnosis. The diagnosis is established through clinical evaluation, serum creatine kinase measurement, electromyography, muscle biopsy, and now, increasingly, genetic testing. Differential diagnoses include other forms of muscular dystrophy such as dystrophinopathies and other LGMD subtypes. Immunohistochemical staining for dysferlin is particularly useful. There is no curative treatment; management is supportive with physiotherapy, occupational therapy, and orthopedic interventions as needed. Emerging therapies are being studied in clinical trials. In pregnancy and lactation, management remains supportive; careful multidisciplinary planning is advised, ensuring that physical activity is optimized and complications are minimized. Option A (Dysferlinopathy) is correct as the clinical context of gastrocnemius atrophy fits with conditions like Miyoshi myopathy, which are due to dysferlin gene mutations. The other options are either blank or unrelated, making A the clear choice. 1. Dysferlinopathy often presents with calf (gastrocnemius) muscle atrophy. 2. Immunohistochemical analysis showing absent dysferlin is diagnostic. 3. Early multidisciplinary support can improve quality of life. Recent studies emphasize the role of next-generation sequencing in diagnosing dysferlinopathies. Research into gene therapies and novel pharmacological approaches is ongoing, though current management remains supportive.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Most common cause of polyradiculoneuropathy:",
    "option_a": "CMV",
    "option_b": "West Nile",
    "option_c": "In HIV",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Polyradiculoneuropathy is an umbrella term for disorders affecting multiple nerve roots and peripheral nerves. Guillain-Barr\u00e9 syndrome (GBS) is the prototypical acute inflammatory polyradiculoneuropathy, with various infectious triggers. GBS is an immune-mediated condition usually triggered by an antecedent infection. Molecular mimicry between microbial antigens and peripheral nerve components leads to an autoimmune attack on myelin and/or axons. Among infections, Campylobacter jejuni is the most common trigger overall, but among viruses, Cytomegalovirus (CMV) is frequently implicated. Patients typically present with rapidly ascending weakness, areflexia, and sometimes sensory disturbances. A history of a recent infection is often reported. Viral infections such as CMV, HIV, and West Nile virus can precipitate the condition, but in the context of the available options, CMV is most commonly associated with GBS. Diagnosis is based on clinical history, cerebrospinal fluid analysis (showing albuminocytologic dissociation), and nerve conduction studies demonstrating demyelination and/or axonal involvement. Differentials include other causes of acute weakness such as myasthenia gravis, botulism, and spinal cord pathology. First-line treatments include intravenous immunoglobulin (IVIG) and plasmapheresis. Both therapies have proven efficacy and are considered safe during pregnancy; IVIG is especially preferred owing to its ease of administration and safety profile in lactating women. Supportive care in an intensive care setting may be needed for respiratory compromise. Option A (CMV) is considered correct in this context, as CMV is a well-recognized viral trigger for GBS. Option B (West Nile) and Option C (HIV) are known to be associated with neuropathies but are less common triggers compared to CMV in the context of polyradiculoneuropathy. The marked answer D is not a viable option as it is undefined. 1. Campylobacter jejuni is the most common antecedent pathogen in GBS overall, but among viruses, CMV is a key trigger. 2. Early treatment with IVIG or plasmapheresis improves outcomes. 3. GBS can affect respiratory muscles, warranting close monitoring. Recent guidelines by neurology societies continue to endorse IVIG and plasmapheresis as first-line therapies for GBS. There is ongoing research into optimized treatment timing and the role of adjunctive therapies, with special protocols developed for managing GBS in pregnant and lactating patients.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of CMT with episodic dysarthria, ataxia (CNS involvement), NCS done shows severely affected amplitudes for motor and sensory but preserved velocity and latency (axonal) what is the type:",
    "option_a": "Cmt 1",
    "option_b": "cmt 2",
    "option_c": "cmt 3",
    "option_d": "cmtx",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot-Marie-Tooth (CMT) disease is a group of inherited peripheral neuropathies characterized by progressive weakness and sensory loss. It is subdivided into various types based on inheritance pattern, electrophysiological findings, and genetic mutations. CMTX (X-linked CMT) is one type that can occasionally involve the central nervous system (CNS). CMTX is caused by mutations in the GJB1 gene, which encodes connexin 32. This protein is expressed in Schwann cells of the peripheral nervous system and in oligodendrocytes in the CNS. Dysfunction in connexin 32 leads to impaired gap junction communication, resulting in nerve degeneration. The unique aspect of CMTX is its potential to cause transient CNS manifestations, such as dysarthria and ataxia, in addition to peripheral nerve involvement. Patients with CMT typically present with slowly progressive distal weakness and sensory loss. In CMTX, episodes of dysarthria and ataxia suggest transient CNS involvement, which distinguishes it from other types. The nerve conduction study (NCS) findings, showing severely reduced amplitudes (reflecting axonal loss) but preserved conduction velocities and latencies, are more consistent with an axonal neuropathy. Electrophysiological studies differentiate between demyelinating (e.g., CMT1) and axonal (e.g., CMT2) forms. However, the presence of CNS signs such as dysarthria and ataxia is a hallmark of CMTX. Genetic testing for GJB1 mutations confirms the diagnosis. Differential diagnoses include other hereditary neuropathies like CMT1 (demyelinating) and CMT2 (axonal) and acquired conditions such as chronic inflammatory demyelinating polyneuropathy (CIDP). There is no cure for CMT; management focuses on supportive care including physical therapy, occupational therapy, and the use of orthotic devices to assist ambulation. Pain management and vocational rehabilitation are also important. In pregnancy and lactation, multidisciplinary management ensures continued mobility and safety, with physiotherapy and tailored exercise programs being essential recommendations. Option A (CMT 1) is typically a demyelinating neuropathy and does not feature CNS involvement. Option B (CMT 2) is an axonal neuropathy but lacks the central features. Option C (CMT 3) represents a severe early-onset demyelinating form. Option D (CMTX) is the correct answer because it uniquely can present with episodic dysarthria and ataxia, reflecting CNS involvement, while the NCS findings can be consistent with an axonal pattern in advanced disease. 1. CMTX should be suspected in patients with both peripheral neuropathy and transient central nervous system symptoms. 2. Nerve conduction studies may show preserved conduction velocities with low amplitudes in axonal variants. 3. Genetic testing for GJB1 mutations is confirmatory. Recent research has reinforced the association between GJB1 mutations and variable presentations of CMTX, including CNS involvement. Advances in electrophysiological techniques and genetic testing have improved the accuracy of subtype diagnosis, which is crucial for targeted patient counseling and management.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A young woman who was recently diagnosed with DM which was not controlled at all after admission to hospital with DKA and HBA1c of 14, then his RBS reading became around 100 (well controlled) patient discharged and her blood sugar was controlled adequately however she developed peripheral painful neuropathy, what is the rx:",
    "option_a": "gabapentin",
    "option_b": "steroid",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario illustrates a case of treatment\u2010induced neuropathy in a diabetic patient. After a period of very poor glycemic control (e.g., DKA with an HbA1c of 14), the patient\u2019s rapid normalization of blood sugar (RBS around 100) precipitates a peripheral, painful neuropathy. It is an example of an iatrogenic phenomenon sometimes called insulin neuritis. The exact mechanism isn\u2019t completely understood, but it is thought that a rapid shift in blood glucose levels leads to changes in nerve blood flow and metabolic stress. This can result in endoneurial hypoxia or microvascular damage, triggering nerve fiber injury. There may also be an immunologic component that contributes to the nerve damage following abrupt glycemic improvement. Patients with treatment-induced neuropathy typically present with acute onset of burning or lancinating pain in the extremities after a rapid improvement in glycemic control. This contrasts with the gradual onset seen in chronic diabetic neuropathy. The temporal relationship to normalization of blood sugars is a key clinical pointer. Clinical history is paramount. Differential diagnoses include chronic diabetic neuropathy, nerve compression syndromes, or other causes of small fiber neuropathy. Electrophysiologic studies (nerve conduction studies) can help distinguish between these types, although the diagnosis is largely clinical. History of a recent, rapid change in blood sugar control is the distinguishing feature. Management is primarily symptomatic: \n\u2022 First-line: Gabapentin, pregabalin, or other neuropathic pain agents (such as duloxetine or TCAs) are recommended to control pain symptoms. \n\u2022 Second-line: Dose adjustments and combination therapy may be considered if monotherapy is insufficient. \n\u2022 Glycemic management: Continued but gradual glycemic control is advised to avoid recurrence. \nPregnancy/Lactation Considerations: Many neuropathic agents (including gabapentin) are classified as Category C; risks and benefits must be weighed, and alternative agents with a better safety profile in pregnancy may be considered if necessary. Option A (gabapentin) is correct as it is a first-line therapy for neuropathic pain. Option B (steroid) is not indicated in this situation and has no proven benefit in treatment\u2010induced neuropathy. \u2022 Rapid normalization of blood sugar in chronically uncontrolled diabetes can paradoxically precipitate painful neuropathy.  \u2022 Gabapentin (or similar agents) is the mainstay for symptomatic relief of neuropathic pain in these settings. Recent literature and guidelines emphasize the importance of gradual glycemic improvement to minimize the risk of treatment-induced neuropathy. Moreover, gabapentin and related medications remain the cornerstone for managing neuropathic pain, as reflected in updated diabetic neuropathy management guidelines.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "scenario of old pt. With neuropathy and weakness (?asking about amyloidosis) what to do:",
    "option_a": "fat aspiration",
    "option_b": "immunofixation",
    "option_c": "plasma electrophoresis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B,C",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses the initial workup for suspected amyloidosis in an elderly patient presenting with neuropathy and weakness. Amyloidosis, particularly AL (primary) amyloidosis, is known for its multisystem involvement which can include peripheral neuropathy. AL amyloidosis results from a plasma cell disorder in which misfolded immunoglobulin light chains deposit in tissues, causing organ dysfunction. These deposits can impair neural function, leading to symptoms such as neuropathy and muscle weakness. In older patients, the combination of neuropathy with systemic signs (including weakness) should prompt evaluation for amyloidosis. Neuropathy in this context is often a clue to a systemic plasma cell dyscrasia, which may be confirmed by laboratory tests demonstrating monoclonal protein. The initial workup includes noninvasive laboratory tests such as serum protein electrophoresis, serum immunofixation electrophoresis, and serum free light chain assay to detect monoclonal gammopathy. Although fat pad aspiration (abdominal fat biopsy) is used as a confirmatory test because of its high specificity and ease, screening with immunofixation and plasma electrophoresis is typically prioritized. Once AL amyloidosis is confirmed, treatment involves targeting the plasma cell clone using regimens that might include proteasome inhibitors (e.g., bortezomib), immunomodulatory drugs, and sometimes autologous stem cell transplant if the patient is eligible. \n\u2022 First-line: Chemotherapy regimens tailored to the patient\u2019s overall condition and organ involvement. \n\u2022 Second-line: Novel agents or enrollment in clinical trials if refractory. \nPregnancy/Lactation Considerations: Most chemotherapeutic agents used for amyloidosis are contraindicated during pregnancy and lactation; management in women of childbearing potential requires careful risk-benefit assessment and potential deferral until postpartum. Option B (immunofixation) and option C (plasma electrophoresis) are both noninvasive screening tests that are appropriate for detecting a monoclonal protein, which is key in diagnosing AL amyloidosis. Option A (fat aspiration) is a useful confirmatory test; however, the initial evaluation is best served by the laboratory screening tests, making B and C the more immediate answers. \u2022 Always initiate suspicion of amyloidosis with noninvasive tests like serum immunofixation and plasma electrophoresis before proceeding to tissue biopsy.  \u2022 Neuropathy and unexplained weakness in an older patient warrant evaluation for an underlying plasma cell dyscrasia. Recent guidelines recommend a combination of serum free light chain assay with immunofixation electrophoresis as the first step in workup for suspected AL amyloidosis. The role of fat pad aspiration remains important for tissue confirmation, but it is usually pursued after abnormal screening results.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario with stiffness and difficult walking with episode of LOC Emg showed neuromyotonia and now pt is fully conscious normal mental status (question is conflicting between Isaac and morvan), and gene found K gated channel, what is Dx:",
    "option_a": "Morvan syndrome",
    "option_b": "Isaac syndrome",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question differentiates between two syndromes that have overlapping features: Isaacs syndrome (acquired neuromyotonia) and Morvan syndrome. Both are associated with antibodies against voltage-gated potassium channels (VGKC), but they differ in the extent of central nervous system (CNS) involvement. Isaacs syndrome is characterized by peripheral nerve hyperexcitability resulting in continuous muscle fiber activity. Morvan syndrome, while also featuring neuromyotonia, additionally involves CNS symptoms such as encephalopathy, confusion, and sometimes autonomic dysfunction. The detection of VGKC antibodies can be seen in both, but the clinical picture distinguishes them. The patient\u2019s presentation includes stiffness, difficulty walking, and neuromyotonia on electromyography. The absence of persistent CNS symptoms (the patient is now fully conscious and has a normal mental status despite an episode of loss of consciousness) strongly favors Isaacs syndrome over Morvan syndrome, which would typically manifest with ongoing encephalopathy or marked cognitive disturbances. Diagnosis relies on correlating clinical presentation with electrophysiologic findings and antibody testing. Differential diagnoses include stiff-person syndrome (which has a distinct clinical and EMG profile) and other conditions causing muscle hyperexcitability. In Isaacs syndrome, the absence of significant CNS involvement is the key differentiator from Morvan syndrome. Treatment for both conditions often involves symptomatic management with anticonvulsants (like carbamazepine, phenytoin) and may include immunomodulatory therapies (e.g., corticosteroids, IVIG) if an autoimmune etiology is confirmed. \n\u2022 First-line: Symptomatic management with anticonvulsants for muscle stiffness and cramps. \n\u2022 Second-line: Immunosuppressants or IVIG in refractory cases. \nPregnancy/Lactation Considerations: When considering immunomodulatory treatments in pregnant or lactating patients, the risks of immunosuppressive agents must be carefully balanced against maternal benefits, and agents with known safety profiles in pregnancy should be favored. Option A (Morvan syndrome) is incorrect because Morvan syndrome typically presents with prominent CNS symptoms such as confusion, hallucinations, or sleep disturbances, which are absent in this patient. Option B (Isaacs syndrome) is the correct diagnosis because the patient\u2019s symptoms (peripheral neuromyotonia with preserved mental status) align with this condition. \u2022 Isaacs syndrome (acquired neuromyotonia) presents with muscle stiffness and fasciculations without significant CNS involvement.  \u2022 In contrast, Morvan syndrome is marked by both peripheral nerve hyperexcitability and prominent central features, such as encephalopathy. Recent studies emphasize the importance of clinical context in interpreting VGKC antibody positivity. While both syndromes share immunologic markers, the full clinical picture \u2014 especially the presence or absence of CNS symptoms \u2014 remains essential for accurate diagnosis.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Young with one eye visual loss then develop hearing loss:",
    "option_a": "Susac",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question pertains to Susac syndrome, a rare autoimmune microangiopathy that primarily affects young individuals, especially women. The syndrome is classically defined by a triad involving retinal artery occlusions (causing visual deficits), sensorineural hearing loss, and encephalopathy. Susac syndrome is believed to be an autoimmune endotheliopathy that results in microinfarctions in the brain, retina, and cochlea. The occlusion of small arterial vessels leads to the characteristic clinical manifestations. Although the complete triad may not present simultaneously, the combination of visual and auditory symptoms in a young patient is highly suggestive. In this case, the patient initially experienced visual loss in one eye, followed by hearing loss. While the full triad is not described, the combination of these findings in a young patient should prompt consideration of Susac syndrome. Encephalopathy may develop later or may be subtle in the early phases. Diagnostic workup involves neuroimaging (typically MRI showing distinctive corpus callosum lesions), retinal fluorescein angiography (to identify branch retinal artery occlusions), and audiometric testing. Differential diagnoses include multiple sclerosis, vasculitis, and other demyelinating disorders, but the unique pattern of retinal and cochlear involvement in Susac syndrome helps differentiate it. The mainstay of treatment is immunosuppression: \n\u2022 First-line: High-dose corticosteroids are usually initiated to control inflammation. \n\u2022 Second-line: Other immunosuppressive agents (e.g., IVIG, mycophenolate mofetil, or cyclophosphamide) may be employed in refractory cases. \nPregnancy/Lactation Considerations: Corticosteroids are commonly used in pregnancy, although their use must be monitored carefully. Other immunosuppressants require careful risk-benefit analysis in pregnant or lactating women, with alternatives considered based on safety profiles. Option A (Susac syndrome) is correct because the clinical presentation of visual loss and subsequent hearing loss in a young patient fits the syndrome well. Other options are either not provided or less appropriate in this context. \u2022 Susac syndrome should be considered in young patients presenting with unexplained visual and auditory deficits, even if encephalopathy is not prominent initially.  \u2022 Early recognition and immunosuppressive treatment are crucial to prevent permanent neurological and sensory damage. Recent research highlights the benefit of early aggressive immunosuppression in Susac syndrome to reduce long-term sequelae. Advances in neuroimaging and retinal imaging have improved diagnostic accuracy, and current guidelines stress multidisciplinary management.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A patient presented with falling down with acetabulum fracture after admission he still has very painful right leg however, he noticed that he could not dorsiflex his right foot along with decreased sensation of the dorsum of right feet, what is most likely injured in this patient:",
    "option_a": "Sciatic nerve main trunk",
    "option_b": "medial portion of sciatic nerve",
    "option_c": "lateral portion of sciatic nerve (common peroneal)",
    "option_d": "Lateral > common",
    "option_e": "Medial > tibial",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The sciatic nerve bifurcates into two major divisions: the tibial and common peroneal (lateral) nerves. The common peroneal nerve specifically innervates the muscles involved in dorsiflexion of the foot and provides sensory innervation to the dorsum of the foot. In trauma such as an acetabulum fracture, the sciatic nerve may be injured. However, the common peroneal division is more susceptible to injury because of its relatively fixed course and limited connective tissue support compared to the tibial division. Damage to this nerve results in loss of function in its motor branches (resulting in foot drop) and sensory deficits in its cutaneous distribution. The patient\u2019s inability to dorsiflex the foot (foot drop) and decreased sensation over the dorsum of the foot are classical indicators of common peroneal nerve injury. This correlates well with the known distribution and function of the nerve. Diagnosis is clinical, based on neurological examination. Electrophysiologic studies (nerve conduction studies and electromyography) can confirm the lesion and determine severity. Differential diagnoses include L4 radiculopathy or knee injuries, but these are ruled out by a targeted exam focusing on the distribution of deficits. Initial management includes pain control, physical therapy, and the use of an ankle\u2013foot orthosis to prevent falls. In cases where nerve compression or entrapment is suspected, surgical decompression might be indicated. In the context of trauma, stabilization and repair of associated fractures are critical. Pregnancy and lactation considerations involve selecting pain medications and physical therapy measures that are safe; most non-invasive supportive measures remain unchanged in these populations. Option A (Sciatic nerve main trunk) would cause a broader deficit (both tibial and common peroneal territories). Option B (medial portion) is not anatomically specific regarding the branches affected, as the tibial component (medial) would cause deficits different from foot drop. Option C (lateral portion of sciatic nerve - common peroneal) most accurately explains the clinical picture. Options D and E, though worded to indicate a predominance of involvement, reiterate the same anatomical distribution but are less precise than option C. 1. In acetabulum and hip injuries, always evaluate for sciatic nerve injury, with foot drop as a key indicator. 2. The common peroneal nerve\u2019s lack of robust connective tissue support makes it particularly vulnerable in trauma. Recent trauma guidelines emphasize early neurological evaluation and appropriate imaging to identify nerve involvement. Electrophysiological testing remains the gold standard to quantify the extent of nerve injury, and current clinical practice supports conservative management with physiotherapy as first-line therapy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "vague scenario for young with neuropathy, headache and visual symptoms MRI provided showing anterior temporal and occipital changes vs atrophy what to do :",
    "option_a": "skin biopsy",
    "option_b": "muscle biopsy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The scenario described\u2014a young patient with headache, visual disturbances, and MRI changes involving the anterior temporal (and possibly occipital) lobes\u2014raises suspicion for a cerebral small vessel disease. In particular, CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) commonly involves the anterior temporal lobes on imaging. CADASIL is a hereditary arteriopathy caused by mutations in the NOTCH3 gene. This mutation leads to degeneration of vascular smooth muscle cells and the accumulation of granular osmiophilic material (GOM) in small cerebral arteries, resulting in subcortical infarcts and leukoencephalopathy, predominantly affecting the anterior temporal regions. Patients with CADASIL typically present with recurrent migraine headaches (often with aura), mood disturbances, and subcortical ischemic events that may lead to cognitive impairment. While peripheral neuropathy is not a hallmark of CADASIL, the constellation of central symptoms and characteristic MRI findings directs attention to this diagnosis. The diagnosis of CADASIL is based on clinical history, characteristic MRI findings (particularly white matter hyperintensities in the anterior temporal lobes), and can be confirmed with genetic testing for NOTCH3 mutations. A skin biopsy demonstrating granular osmiophilic deposits can be used if genetic testing is inconclusive or not available. Differential diagnoses include multiple sclerosis, mitochondrial disorders, and other hereditary leukoencephalopathies, which can be distinguished based on the pattern of MRI findings and genetic tests. There is no cure for CADASIL. Management focuses on controlling vascular risk factors (e.g., hypertension) and symptomatic treatment of migraines and mood disorders. Preventative antiplatelet therapy may be considered in patients with recurrent ischemic events. In pregnant or lactating patients, management must carefully weigh the risks of antiplatelet agents and other medications, often favoring non-pharmacologic measures when possible. Genetic counseling is recommended for family planning. Option A (skin biopsy) is classically used to demonstrate the granular deposits in the smooth muscle cells of small arteries in CADASIL and is therefore correct. Option B (muscle biopsy) is not indicated in this scenario as it is more appropriate for diagnosing myopathic or mitochondrial disorders. 1. The presence of anterior temporal lobe white matter changes on MRI is highly suggestive of CADASIL. 2. Although genetic testing is the current diagnostic standard, skin biopsy remains a useful tool in cases where genetic testing is not available or inconclusive. Recent research advocates for early genetic screening in suspected CADASIL cases, but skin biopsy remains a valid diagnostic adjunct. Updated studies emphasize the importance of risk factor modification and symptomatic treatment, as no disease-modifying therapies currently exist.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Long scenario for Pt. With neuropathy and asthma what to do:",
    "option_a": "ANCA",
    "option_b": "Churg Strauss",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical scenario features a patient with a history of asthma and neuropathy. This combination is highly characteristic of Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome. EGPA is a small- to medium-vessel vasculitis that is strongly associated with asthma and eosinophilia. The underlying immune dysregulation leads to granulomatous inflammation and necrotizing vasculitis, which can cause multisystem involvement including peripheral nerves, resulting in neuropathy (often as a mononeuritis multiplex). Patients with EGPA typically present with longstanding asthma, allergic rhinitis, and systemic features such as fever and weight loss. The neuropathy is usually due to vascular inflammation leading to nerve ischemia. The presence of asthma in a patient with new-onset peripheral neuropathy strongly suggests EGPA. The diagnosis relies on a combination of clinical criteria (as outlined by the American College of Rheumatology) and laboratory findings including peripheral eosinophilia and positive ANCA in approximately 40% of cases. Nerve conduction studies, biopsy of affected tissues (e.g., sural nerve or skin), and imaging can support the diagnosis. Differential diagnoses include other ANCA-associated vasculitides (e.g., microscopic polyangiitis) and allergic granulomatosis, but the presence of asthma and eosinophilia is distinguishing. First-line treatment for EGPA is systemic corticosteroids. For patients with severe or refractory disease, immunosuppressants such as cyclophosphamide may be added. Newer agents like mepolizumab (an anti-IL5 monoclonal antibody) have been employed in refractory cases. In pregnant or lactating patients, corticosteroids remain the mainstay while careful consideration is required for additional immunosuppressants due to teratogenic risks. Option A (ANCA) represents a laboratory test that can support the diagnosis but is not the diagnosis itself. Option B (Churg-Strauss) correctly identifies the clinical syndrome (EGPA). Options C and D are missing, making B the most correct answer given the context. 1. EGPA is the only vasculitis that has a strong association with asthma and eosinophilia. 2. Peripheral neuropathy, commonly presenting as mononeuritis multiplex, is a frequent complication of EGPA. Current guidelines advocate for early recognition and a tiered immunosuppressive treatment strategy in EGPA. Emerging treatments such as biologics targeting interleukin-5 are showing promising results in reducing steroid dependence and improving outcomes.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A man with long history of malnutrition presented with peripheral neuropathy, ataxia, deafness and retinal degeneration and optic atrophy was diagnosed with Strachan syndrome which is a deficiency in:",
    "option_a": "vitamin A",
    "option_b": "vitamin E",
    "option_c": "vitamin B12",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Strachan syndrome, as described, is associated with malnutrition leading to a deficiency; its clinical picture (peripheral neuropathy, ataxia, deafness, and retinal degeneration with optic atrophy) is most consistent with vitamin E deficiency. Vitamin E is a crucial antioxidant that protects cell membranes from oxidative damage. Deficiency leads to neuronal oxidative stress and degeneration, particularly affecting the dorsal columns and peripheral nerves. This results in a clinical syndrome that mimics spinocerebellar ataxias with associated neuropathy and retinal degeneration. The combination of malnutrition with neurological deficits\u2014such as ataxia, peripheral neuropathy, and visual impairment\u2014is characteristic of vitamin E deficiency. Patients may also present with hearing loss, which aligns with the described deafness. Diagnosis is established by measuring serum vitamin E levels in the context of malabsorption or malnutrition. Differential diagnoses include vitamin B12 deficiency (which typically presents with megaloblastic anemia and posterior column dysfunction) and vitamin A deficiency (primarily causing night blindness and xerophthalmia). Careful clinical correlation and laboratory testing help differentiate these conditions. The mainstay of treatment for vitamin E deficiency is high-dose vitamin E supplementation. Dietary counseling and management of the underlying malabsorption are critical. In pregnant or lactating patients, vitamin E supplementation is generally safe, but dosing should be adjusted and monitored appropriately. Option A (vitamin A deficiency) is associated mainly with ocular issues like night blindness rather than a neurological syndrome. Option B (vitamin E deficiency) correctly explains the combination of peripheral neuropathy, ataxia, deafness, and retinal degeneration. Option C (vitamin B12 deficiency) can cause neuropathy and ataxia but is less commonly associated with retinal degeneration or deafness. 1. Vitamin E deficiency can present with a syndrome resembling spinocerebellar ataxia. 2. Patients with fat malabsorption or malnutrition are at high risk for vitamin E deficiency and its neurological complications. Recent studies underscore the importance of early detection of vitamin E deficiency in malnourished patients, as timely supplementation can prevent irreversible neurological damage. Updated guidelines recommend routine assessment of fat-soluble vitamin levels in patients with chronic malabsorption.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of patient had mastectomy came with arm pain and dysesthesia over the fourth and fifth finger, what to do next?",
    "option_a": "MRI plexus; (Lower trunk which comes from C8-T1)",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Post\u2010mastectomy patients can develop neuropathic symptoms due to iatrogenic injury to the brachial plexus. When pain and dysesthesia localize to the fourth and fifth fingers, this is highly suggestive of a lower trunk (C8-T1) involvement. During mastectomy\u2014especially when axillary lymph node dissection is performed\u2014the lower trunk of the brachial plexus is at risk for traction or direct injury. Damage to these nerve fibers results in demyelination and/or axonal injury leading to neuropathic pain and sensory disturbances in the ulnar distribution. Patients typically report arm pain and paresthesias specifically in the region supplied by the ulnar nerve (medial side of the forearm, fourth and fifth digits). These findings correlate well with an injury to the lower trunk of the brachial plexus (C8-T1). The initial diagnostic step is to anatomically localize the injury. Magnetic resonance imaging (MRI) of the brachial plexus is the modality of choice as it provides excellent soft tissue resolution and can detail nerve continuity, edema, and possible scarring. Differential diagnoses include post-surgical neuroma, radiation-related plexopathy, or tumor recurrence; MRI helps to differentiate these. Management is multidisciplinary. First-line treatment includes pain management, physical therapy, and occupational therapy with a focus on functional recovery. In cases where imaging shows significant structural disruption, neurosurgical consultation may be warranted. In pregnant or lactating patients, MRI is considered safe, especially when performed without gadolinium unless absolutely necessary. Option A (\u2018MRI plexus\u2019) is correct because it offers direct visualization of the lower trunk and surrounding soft tissues, aiding in both diagnosis and potential surgical planning. Other options (not provided) are less optimal for initial anatomical delineation. 1) Dysesthesia in the fourth and fifth fingers strongly suggests lower trunk involvement. 2) MRI is the gold standard imaging modality for brachial plexus injuries due to its excellent soft tissue contrast. Recent studies have reinforced the utility of high-resolution MRI in detecting subtle nerve injuries and in surgical planning. Updated guidelines emphasize early imaging to accurately classify the extent of brachial plexus involvement.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of ALS, NCS/ EMG findings?",
    "option_a": "Fasiculation",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Post\u2010mastectomy patients can develop neuropathic symptoms due to iatrogenic injury to the brachial plexus. When pain and dysesthesia localize to the fourth and fifth fingers, this is highly suggestive of a lower trunk (C8-T1) involvement. During mastectomy\u2014especially when axillary lymph node dissection is performed\u2014the lower trunk of the brachial plexus is at risk for traction or direct injury. Damage to these nerve fibers results in demyelination and/or axonal injury leading to neuropathic pain and sensory disturbances in the ulnar distribution. Patients typically report arm pain and paresthesias specifically in the region supplied by the ulnar nerve (medial side of the forearm, fourth and fifth digits). These findings correlate well with an injury to the lower trunk of the brachial plexus (C8-T1). The initial diagnostic step is to anatomically localize the injury. Magnetic resonance imaging (MRI) of the brachial plexus is the modality of choice as it provides excellent soft tissue resolution and can detail nerve continuity, edema, and possible scarring. Differential diagnoses include post-surgical neuroma, radiation-related plexopathy, or tumor recurrence; MRI helps to differentiate these. Management is multidisciplinary. First-line treatment includes pain management, physical therapy, and occupational therapy with a focus on functional recovery. In cases where imaging shows significant structural disruption, neurosurgical consultation may be warranted. In pregnant or lactating patients, MRI is considered safe, especially when performed without gadolinium unless absolutely necessary. Option A (\u2018MRI plexus\u2019) is correct because it offers direct visualization of the lower trunk and surrounding soft tissues, aiding in both diagnosis and potential surgical planning. Other options (not provided) are less optimal for initial anatomical delineation. 1) Dysesthesia in the fourth and fifth fingers strongly suggests lower trunk involvement. 2) MRI is the gold standard imaging modality for brachial plexus injuries due to its excellent soft tissue contrast. Recent studies have reinforced the utility of high-resolution MRI in detecting subtle nerve injuries and in surgical planning. Updated guidelines emphasize early imaging to accurately classify the extent of brachial plexus involvement.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient had bariatric surgery developed weakness and large fiber neuropathy, normal B12 and MMA \u2192 Copper",
    "option_a": "(\u2018MRI plexus\u2019) is correct because it offers direct visualization of the lower trunk and surrounding soft tissues, aiding in both diagnosis and potential surgical planning. Other options (not provided) are less optimal for initial anatomical delineation.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Coppe",
    "subspecialty": "Neuromuscular",
    "explanation": "Post\u2010mastectomy patients can develop neuropathic symptoms due to iatrogenic injury to the brachial plexus. When pain and dysesthesia localize to the fourth and fifth fingers, this is highly suggestive of a lower trunk (C8-T1) involvement. During mastectomy\u2014especially when axillary lymph node dissection is performed\u2014the lower trunk of the brachial plexus is at risk for traction or direct injury. Damage to these nerve fibers results in demyelination and/or axonal injury leading to neuropathic pain and sensory disturbances in the ulnar distribution. Patients typically report arm pain and paresthesias specifically in the region supplied by the ulnar nerve (medial side of the forearm, fourth and fifth digits). These findings correlate well with an injury to the lower trunk of the brachial plexus (C8-T1). The initial diagnostic step is to anatomically localize the injury. Magnetic resonance imaging (MRI) of the brachial plexus is the modality of choice as it provides excellent soft tissue resolution and can detail nerve continuity, edema, and possible scarring. Differential diagnoses include post-surgical neuroma, radiation-related plexopathy, or tumor recurrence; MRI helps to differentiate these. Management is multidisciplinary. First-line treatment includes pain management, physical therapy, and occupational therapy with a focus on functional recovery. In cases where imaging shows significant structural disruption, neurosurgical consultation may be warranted. In pregnant or lactating patients, MRI is considered safe, especially when performed without gadolinium unless absolutely necessary. Option A (\u2018MRI plexus\u2019) is correct because it offers direct visualization of the lower trunk and surrounding soft tissues, aiding in both diagnosis and potential surgical planning. Other options (not provided) are less optimal for initial anatomical delineation. 1) Dysesthesia in the fourth and fifth fingers strongly suggests lower trunk involvement. 2) MRI is the gold standard imaging modality for brachial plexus injuries due to its excellent soft tissue contrast. Recent studies have reinforced the utility of high-resolution MRI in detecting subtle nerve injuries and in surgical planning. Updated guidelines emphasize early imaging to accurately classify the extent of brachial plexus involvement.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario?",
    "option_a": "MRI of plexus then EMG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "EMG/NCS first then MRI",
    "subspecialty": "Neuromuscular",
    "explanation": "In evaluating a suspected brachial plexopathy (or a related nerve plexus disorder), the initial objective is to confirm nerve involvement and localize the lesion. Electrodiagnostic studies (EMG/NCS) are used as the first-line tests because they provide functional information about the nerve, including the presence of axonal loss, demyelination, and localization of conduction block. Once an abnormality is identified, MRI is then employed to anatomically characterize the lesion (e.g., compression, neoplastic processes, or inflammatory changes). Brachial plexopathy involves injury or dysfunction of the nerve fibers in the brachial plexus. This can result from trauma, entrapment, inflammatory conditions, or neoplastic processes. EMG/NCS detect changes due to denervation or conduction block, whereas MRI reveals structural alterations like edema, fibrosis, or mass effect on the nerves. Patients typically present with pain, paresthesias, motor weakness, or sensory deficits in the upper limb. EMG/NCS help differentiate between a radiculopathy (nerve root involvement) and a true plexopathy, assisting in narrowing the differential diagnosis based on distribution and severity of findings. The recommended diagnostic sequence is clinical evaluation followed by EMG/NCS. Once electrophysiologic studies localize and characterize the nerve dysfunction, an MRI (preferably without gadolinium in pregnancy) is used to assess the structural integrity of the plexus and surrounding tissues. This two-step approach avoids unnecessary imaging when the nerve injury pattern is not yet defined. Management principles include confirming the diagnosis with EMG/NCS, then performing MRI to evaluate for structural causes that may require specific treatment (like surgical decompression or tumor resection). In the context of pregnancy and lactation, both EMG and MRI are safe diagnostic modalities when performed appropriately (MRI should be done without contrast agents such as gadolinium unless absolutely necessary, given potential risks during pregnancy). Option A suggested performing an MRI of the plexus first then EMG; however, the marked and evidence-based answer is to initially perform EMG/NCS followed by MRI. The rationale is that electrophysiologic studies help localize and functionally characterize the lesion, directing the subsequent imaging evaluation for anatomical detail. \u2022 Always start with a detailed neurological exam and history.\u2022 EMG/NCS provide key functional insights that guide further imaging.\u2022 MRI should preferably be performed after EMG/NCS unless there is compelling evidence of a structural lesion.\u2022 In pregnancy, non-contrast MRI and EMG/NCS are safe options for evaluating brachial plexopathies. Recent reviews and clinical practice guidelines support the strategy of performing EMG/NCS first in suspected brachial plexopathies. This approach allows for accurate localization/intensity assessment, which then informs the need and timing of MRI, especially in situations where the clinical picture is ambiguous. Safety data affirm that these studies are appropriate in pregnant and lactating patients when executed with the necessary precautions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Mees line? Arsenic \u2191",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "T",
    "subspecialty": "Neuromuscular",
    "explanation": "Mees' lines are transverse white bands seen on the nails that serve as a clinical clue to systemic disturbances. They are classically associated with arsenic poisoning, where exposure to arsenic disrupts normal nail formation. Arsenic poisoning leads to arsenic deposition in the nail bed. This disrupts keratinization and the normal growth of the nail matrix, resulting in the formation of white, transverse lines. The toxicity also causes peripheral nerve damage and systemic symptoms, as supported by current research on heavy metal toxicity. Patients with arsenic toxicity may present with Mees' lines along with other features such as peripheral neuropathy, gastrointestinal disturbances, and skin changes (hyperkeratosis, hyperpigmentation). The presence of these lines in a patient with a history of exposure is a supportive diagnostic clue. Diagnosis is based on a thorough history (exposure to arsenic), clinical examination (presence of Mees' lines and neuropathic features), and laboratory tests including urinary arsenic levels. Differential diagnoses include thallium poisoning (which can also cause nail changes but with additional specific systemic findings) and other heavy metal toxicities. Management focuses on cessation of exposure and initiation of chelation therapy (e.g., Dimercaprol or succimer/DMSA) as first-line treatment. Supportive care is essential for symptom management. In pregnancy, chelation must be used cautiously due to potential teratogenic effects, and the risk\u2013benefit ratio must be carefully evaluated. Lactating patients should also be managed under close supervision as some chelators can be excreted in breast milk. Although the question provided no explicit options, the intended correct association is between Mees' lines and arsenic toxicity. Other potential distractors might include toxins or conditions like thallium poisoning, but arsenic remains the classic cause taught in clinical practice. 1. Mees' lines are a hallmark of arsenic poisoning, but similar nail findings may occasionally be seen in other systemic illnesses. 2. A careful environmental and occupational history is crucial when encountering these nail changes. Recent studies continue to support the role of chelation therapy in the management of arsenic poisoning while emphasizing early recognition of nail changes as a vital clue. Current guidelines reinforce a detailed history assessment and cautious use of chelation in special populations such as pregnant and breastfeeding women.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Agent can cause sensory ataxia, vibration, and proprioception loss:",
    "option_a": "Pyridoxine toxicity",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Sensory ataxia, vibration, and proprioception loss are clinical signs typically resulting from impairment of the dorsal columns of the spinal cord or large-fiber peripheral nerves. Certain agents can directly induce neuropathy affecting these pathways. High doses of pyridoxine (vitamin B6) are neurotoxic and can cause damage to the dorsal root ganglia and peripheral sensory fibers. This toxicity primarily affects large myelinated fibers responsible for proprioception and vibration sensation, leading to a sensory neuropathy that manifests as ataxia. Clinically, patients exposed to high doses of vitamin B6 may present with sensory deficits including loss of vibration and proprioceptive sensations, leading to unsteady gait (sensory ataxia). This presentation must be differentiated from other causes of dorsal column dysfunction such as vitamin B12 deficiency, which may have additional systemic signs. The diagnosis is made primarily on clinical grounds with a history of high-dose pyridoxine exposure. Laboratory confirmation may involve assessing vitamin levels. Differential diagnoses include vitamin B12 deficiency, nitrous oxide-induced neuropathy, and other toxic exposures; a careful medication and supplement history is critical for differentiation. The mainstay of management is immediate cessation of pyridoxine supplementation. Supportive care and physical rehabilitation may be necessary for patients with significant deficits. In pregnant or lactating women, vitamin B6 supplementation should be carefully dosed as excessive intake can have fetal and neonatal neurotoxicity; guidelines recommend adhering to recommended daily allowances. Option A, pyridoxine toxicity, is the correct answer because high doses of vitamin B6 are known to cause a predominantly sensory neuropathy with ataxia and loss of vibration/proprioception. Other agents (which might be considered in distractor options) generally do not cause this specific pattern of toxicity. 1. High-dose vitamin B6 supplementation can cause irreversible sensory neuropathy if not recognized early. 2. Always check supplement dosages when evaluating patients with unexplained sensory deficits. Recent literature and case reports have reinforced that pyridoxine toxicity is dose-dependent. Regulatory bodies and clinical guidelines now emphasize the importance of not exceeding recommended daily allowances, particularly in over-the-counter supplements.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of FSH. What is the Dx?",
    "option_a": "",
    "option_b": "(Facioscapulohumeral muscular dystrophy) is correct. Other options such as Duchenne muscular dystrophy, limb",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder characterized by progressive weakness of the muscles of the face, scapula, and upper arms. It is recognized by its distinctive pattern of muscle involvement. FSHD is most commonly linked with a contraction in the D4Z4 macrosatellite repeat on chromosome 4q35. This genetic defect leads to aberrant gene expression and subsequent muscle fiber degeneration. The molecular pathology is distinct from other muscular dystrophies and involves epigenetic changes that cause toxicity in affected muscles. Patients with FSHD typically present with facial weakness (difficulty with eye closure and smiling), scapular winging, and later involvement of the upper arms. The onset is often in adolescence or early adulthood. The pattern of muscle involvement is a key clinical clue differentiating it from other dystrophies. The diagnosis is made by correlating clinical findings with genetic testing (demonstrating D4Z4 repeat contraction). Differential diagnoses include Duchenne muscular dystrophy (which presents in early childhood with proximal lower limb involvement), limb-girdle muscular dystrophy (primarily affecting hip and shoulder muscles), myasthenia gravis (fluctuating weakness without true muscle degeneration), and inclusion body myositis (typically affecting older adults with different muscle patterns). There is currently no cure for FSHD. Management is supportive and includes physical therapy, occupational therapy, and orthotic support to maintain function. Regular monitoring and cardiac/respiratory assessments may be warranted in some cases. In the context of pregnancy and lactation, management remains supportive with a focus on optimizing functional capacity and safely managing complications, as there is no specific contraindication to supportive therapies during pregnancy. Option B (Facioscapulohumeral muscular dystrophy) is correct. Other options such as Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myasthenia gravis, or inclusion body myositis can be ruled out based on age of onset, pattern of muscle weakness, and genetic findings. 1. The hallmark of FSHD is early facial weakness with scapular winging. 2. Genetic confirmation through testing for D4Z4 repeat contraction is key to diagnosis. Recent research into FSHD has focused on understanding the epigenetic mechanisms behind D4Z4 repeat contraction and exploring potential gene-based therapies. Current guidelines emphasize genetic counseling and multidisciplinary management to optimize quality of life.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "52 years old female has dyslipidemia on statin, and had pneumonia admitted to the hospital then she started on erythromycin, after few days she developed weakness. Suspected toxic myopathy, what is increased the risk?",
    "option_a": "old age.",
    "option_b": "female",
    "option_c": "recent infection",
    "option_d": "concomitant use of erythromycin",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Statin-induced myopathy is a well-recognized adverse effect that can be exacerbated by drug interactions. The use of certain medications, such as erythromycin, can interfere with statin metabolism, increasing the risk of toxic myopathy. Most statins are metabolized via the cytochrome P450 3A4 (CYP3A4) enzyme system. Erythromycin, a macrolide antibiotic, is a potent inhibitor of CYP3A4. When erythromycin is administered concomitantly with statins (especially those metabolized by CYP3A4 such as simvastatin or lovastatin), plasma levels of the statin are increased, leading to a higher risk of muscle toxicity and myopathy. Patients on statins who develop muscle weakness, pain, or elevated creatine kinase levels after starting erythromycin should raise suspicion for statin-induced toxic myopathy. Risk factors include age, female sex, and recent infections; however, the most critical factor in this case is the drug interaction with erythromycin. Diagnosis is based on clinical history (recent start of erythromycin in a statin-treated patient), physical examination, and laboratory evaluations such as creatine kinase levels. Differential diagnoses include inflammatory myopathies, polymyositis, and other drug-induced myopathies. A detailed medication history is essential to rule out other causes. The first step is discontinuation or dose adjustment of the statin, and avoidance of drug interactions by substituting or temporarily withholding agents like erythromycin. Supportive care, including hydration and monitoring of muscle enzymes, is essential. In pregnant and lactating women, statins are contraindicated due to the risk of fetal malformations and should be discontinued prior to conception or pregnancy. Alternative lipid-lowering strategies should be considered in this population. Option D (concomitant use of erythromycin) is the correct answer. While factors like advanced age, female sex, and recent infection may contribute to the overall risk profile, the most significant and modifiable risk factor in this scenario is the pharmacokinetic interaction caused by erythromycin. 1. Always review potential drug interactions in patients on statins, especially when prescribing CYP3A4 inhibitors like erythromycin. 2. In cases of suspected statin-induced myopathy, promptly evaluate CK levels and consider alternative antibiotics or statin regimens. Recent guidelines and literature highlight the importance of awareness regarding drug\u2013drug interactions with statins. Studies have reinforced that CYP3A4 inhibitors significantly increase the risk of myopathy, leading to updated recommendations for statin use in patients requiring concurrent antibiotic therapy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]